The Manufacturers Life Insurance Company Increases Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

The Manufacturers Life Insurance Company increased its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 6.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,398 shares of the company’s stock after purchasing an additional 5,365 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.17% of Voyager Therapeutics worth $747,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its holdings in Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after buying an additional 1,300 shares in the last quarter. Plato Investment Management Ltd purchased a new stake in Voyager Therapeutics in the 1st quarter worth $38,000. SG Americas Securities LLC purchased a new stake in Voyager Therapeutics in the 2nd quarter worth $85,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Voyager Therapeutics by 104.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock valued at $97,000 after purchasing an additional 5,311 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics during the first quarter valued at about $101,000. Institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on VYGR shares. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Wedbush cut their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.83.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.53% of the company’s stock.

Voyager Therapeutics Trading Up 2.5 %

Shares of VYGR opened at $7.36 on Tuesday. The company’s fifty day simple moving average is $6.51 and its 200-day simple moving average is $7.75. The company has a market cap of $400.34 million, a P/E ratio of -147.20 and a beta of 0.91. Voyager Therapeutics, Inc. has a twelve month low of $5.71 and a twelve month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. The firm had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. During the same period last year, the company earned ($0.51) EPS. Analysts predict that Voyager Therapeutics, Inc. will post -1.44 earnings per share for the current fiscal year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.